Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Prostate cancer (PCa) demonstrates notable disease heterogeneity, with African American men (AAM) experiencing a higher incidence and increased mortality rates compared to their European American (EAM) counterparts. While social determinants of health are key contributors to these differences, underlying biological differences remain important drivers of disease severity and outcomes.
Grade group 5 (GG5) prostate cancer (PCa) carries a less favorable prognosis after standard-of-care (SOC) therapy, necessitating novel therapeutic approaches. High-dose rate brachytherapy (HDRBT) and androgen deprivation therapy (ADT) may modulate immune response in GG5 PCa, particularly in tumors with increased immune content.
Grade group 5 (GG5) prostate cancer (PCa) carries a less favorable prognosis after standard-of-care (SOC) therapy, necessitating novel therapeutic approaches. The current treatment paradigm involves long-course androgen deprivation therapy (ADT) combined with radiation therapy (RT) or surgical resection. RT consists of either external beam radiation therapy (EBRT) monotherapy or EBRT combined with brachytherapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
